SCHEMBL26977065

SCHEMBL26977065

Cc1cn(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 8/20 0.48
▸ MAPT P10636 4/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ AURKA O14965 2/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ KDR P35968 1/20 0.46
▸ PTK2 Q05397 1/20 0.46
▸ FLT3 P36888 3/20 0.45
▸ BRD4 O60885 1/20 0.45
▸ PLK4 O00444 1/20 0.44
▸ CDK4 P11802 1/20 0.44
▸ CDK2 P24941 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ JAK3 P52333 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30671838 1.00 JAK2 (0.48) JAK2MAPTMAPK1MEN1KMT2A
SCHEMBL29113551 0.86 MAPT (0.47) MAPTKMT2AAURKATP53
SCHEMBL26979940 0.85 JAK2 (0.54) JAK2MAPTMAPK1AURKAIGF1R
SCHEMBL26977136 0.84 CCND3 (0.49) JAK2MAPTMAPK1MEN1KMT2A
SCHEMBL26977050 0.84 SYK (0.49) JAK2MAPTMAPK1MEN1KMT2A
SCHEMBL26977501 0.81 JAK2 (0.60) JAK2FLT3JAK3
SCHEMBL29929091 0.81 JAK2 (0.60) JAK2FLT3JAK3
SCHEMBL29113550 0.80 — —
SCHEMBL29113554 0.80 JAK2 (0.47) JAK2AURKAIGF1RKDRPTK2
SCHEMBL30671849 0.76 FLT3 (0.56) JAK2MAPTMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190849-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE TYRA BIOSCIENCES, INC. 2024-06-13 — — US disclosed
EP-4297873-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE Tyra Biosciences, Inc. (US) 2024-01-03 — — EP disclosed
CN-117136184-A Aminopyrimidine compounds and methods of use thereof 泰拉生物科学公司 2023-11-28 — — CN disclosed
WO-2022182972-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE TYRA BIOSCIENCES, INC. (US) 2022-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190849-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE DPYD, TYMP, TYMS JAK2 531/4885MAPT 3848/4885MAPK1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback